Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active

– First-in-human clinical trial of MyopiaX®, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally – Enrollment ongoing in Germany, Spain, the Netherlands, and the United Kingdom Berlin, Germany, June 28, 2023 — Dopavision, a clinical-stage company developing innovative solutions for the management of myopia, today announced an update on its […]

Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer

– Leading translational medicine and neuroscience expert to head Dopavision’s research activities Berlin, Germany, March 21, 2023 — Dopavision, a clinical-stage company pioneering the development of digitally delivered light-based therapeutics, today announced the appointment of Prof. Dr. Jens Ellrich as Chief Scientific Officer. Jens Ellrich brings a wealth of scientific knowledge and extensive experience in […]

Dopavision Appoints Dr. Dirk Sauer as Chair of the Company’s Advisory Board

– Former Head of Novartis’ Ophthalmology Development Unit to provide significant product development expertise and industry network Berlin, Germany, November 16, 2022 — Dopavision, a clinical-stage company pioneering the development of digital therapeutics, today announced the appointment of Dr. Dirk Sauer as Chairman of the Company’s Advisory Board. Dirk Sauer brings an exceptional track record […]

Printable Resources

PRINTABLE RESOURCES Return to Portal Home Downloadable Resource Welcome letter Storyboard EN DOCPPT DE DOCPPT ES DOCPDF PT DOCPDF NL DOCPDF Daily schedule Activity cards Weekly schedule (1) Weekly schedule (2) Monthly schedule PDFPDFPDFPDFPDF PDFPDFPDFPDFPDF PDFPDFPDFPDFPDF PDFPDFPDFPDFPDF PDFPDFPDFPDFPDF Goal chart (1) Goal chart (2) PDFPDF PDFPDF PDFPDF PDFPDF PDFPDF At-home reward system Clinic reward system […]

Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer

– Former Novartis ophthalmology program head significantly strengthens Dopavision’s management capabilities – Company recently initiated clinical trial of novel digital therapeutic for childhood myopia Berlin, Germany, May 25, 2022 — Dopavision, a company pioneering the development of digital therapeutics, today announced that Mark S. Wuttke, Ph.D., has been appointed as the Company’s Chief Executive Officer. […]


FREQUENTLY ASKED QUESTIONS Technical FAQs Trial FAQs Return to Portal Home Technical FAQs Download all FAQs as a PDF This section provides guidance on how to respond to some common technical concerns with which caregivers may reach out to you. If you do not feel confident helping a caregiver with a technical question, please assure […]

Report a Technical Issue

REPORT A TECHNICAL ISSUE Technical Issue Form Return to Portal Home We encourage you to use this form to report technical issues you or participants may be experiencing. The information provided in this form goes directly to our Product team at Dopavision. One of our technical experts will review the report and get in touch […]


Tips How to Navigate Technical Issues How to Report Technical Issues Return to Portal Home Navigating Technical Issues Download as a PDF Dopavision does its best to ensure that the MyopiaX and content apps have no technical issues. Yet, unforeseen technical issues may still occur during the MyopiaX-1 clinical trial. If a participant’s caregiver reports […]


GUIDES Weekly Low Adherence Calls Return to Portal Home Purpose: Understand why children have not been performing the recommended number of treatment sessions over the past week. Download as a PDF Goal: Motivate participating children and their caregivers to resume the twice daily treatment sessions as soon as possible by: Building rapport… inquire about how […]

Ensaio clínico

ENSAIO CLÍNICO O QUE É O ENSAIO CLÍNICO MYOPIAX®? A finalidade deste ensaio é investigar os efeitos clínicos de MyopiaX® MyopiaX® é uma aplicação para smartphone que visa a abrandar a progressão (agravamento) da miopia em crianças e adolescentes. Estamos a levar a cabo um ensaio clínico (NCT04967287) para estudar a segurança e o efeito do […]